Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

CX-516 (Ampalex)

Plain-language summaryIntrigue 48 / 100

CX-516 (ampalex) is the first benzoylpyrrolidine ampakine, developed at Cortex Pharmaceuticals. Phase 2 trials in schizophrenia and Alzheimer were inconclusive. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

First-generation AMPA PAM prototype with poor PK and mixed Phase 2 results, now largely superseded by later ampakines

Look, CX-516 matters historically. It was the compound that proved you could take an AMPA receptor positive allosteric modulator into humans and not immediately break things. Gary Lynch’s group at UC Irvine built a real pharmacological hypothesis around AMPA potentiation driving BDNF release and synaptic consolidation, and Cortex Pharmaceuticals ran it all the way through Phase 2 trials. That took real effort and the mechanism story is still interesting. We dont score for effort, though.

Here’s the thing about CX-516’s pharmacokinetics: they’re bad. Half-life around one to two hours, low oral bioavailability, and doses in the clinical trials running from 200 to 1200 mg administered three to four times daily just to maintain any exposure. That dose burden alone tells you this compound wasnt built for translation. The trials in mild cognitive impairment, schizophrenia cognitive symptoms, and fragile X syndrome all produced results that were mixed at best and insufficient to justify Phase 3 advancement. When three different indications each fail to generate a clear signal, the compound’s translational story becomes very hard to defend.

The AMPA PAM mechanism itself still draws serious attention. Positive allosteric modulation of AMPA receptors can enhance synaptic throughput without the direct receptor overstimulation risks of AMPA agonism, and the downstream effects on BDNF and long-term potentiation are mechanistically coherent. But CX-516 is the weakest version of that story. CX-546 has better PK. CX-614 has better receptor kinetics. If you want to run an ampakine experiment in a rodent model today, there are cleaner probes available. CX-516 retains some value as a reference compound for cross-study comparisons with older literature, but that’s a narrow use case.

What we don’t like: a compound that was the first doesn’t stay the best, and here the field moved on pretty decisively. The Phase 2 failures aren’t disqualifying for the mechanism class, but they are disqualifying for CX-516 as a serious research target. The PK liabilities aren’t a minor issue to work around; they’re the reason this compound never graduated.

Honestly, if you’re running an AMPA potentiation research program, CX-516 belongs in your comparison set and your historical context section, not in your primary experimental arm. It’s the compound that opened the door. Later ampakines walked through it. Score reflects that accurately.

Novelty

22

Mechanism promise

48

In-category differentiation

20

Evidence quality

48

Translational signal

28

Research bench value

38

Rationale CX-516 scores low on novelty and differentiation because it is explicitly a superseded first-generation prototype with known pharmacokinetic liabilities; the AMPA PAM mechanism itself is genuinely interesting and partially salvages the mechanism and bench scores, but Phase 2 failures across three indications hold translational signal down, and later compounds in the same class are simply better tools.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Benzoylpyrrolidine ampakine

The first ampakine to enter human clinical trials, developed at Cortex Pharmaceuticals as a mechanism prototype with limited efficacy.

Abstract

CX-516 (Ampalex; 1-(quinoxalin-6-ylcarbonyl)piperidine; CAS 154235-83-3; molecular formula C14H15N3O; molecular weight 241.29) was the first ampakine compound to enter human clinical trials, developed at Cortex Pharmaceuticals (now RespireRx Pharmaceuticals) under license from Gary Lynch and Gary Rogers at the University of California, Irvine. The compound is a benzoylpyrrolidine class AMPA receptor positive allosteric modulator. CX-516 advanced through Phase 2 trials in mild cognitive impairment, schizophrenia (cognitive symptoms), and fragile X syndrome, with mixed results that did not support advancement to Phase 3. The compound has poor pharmacokinetic properties (very short plasma half-life, approximately 1 to 2 hours, and low oral bioavailability) which limit its clinical utility despite mechanistic interest. CX-516 retains research utility as an AMPA potentiator probe but is largely superseded by later-generation compounds (CX-546, CX-614, and others). Doses in clinical trials ranged from 200 to 1200 mg per administration, three to four times daily. The compound is sold as a research chemical in jurisdictions where it is not scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-054Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
IGF-1 LR3

Plain-language summaryIntrigue 65 / 100

IGF-1 LR3 is a long-acting modified form of insulin-like growth factor 1. The R3 modification reduces binding to IGF-binding proteins, extending the half-life from minutes to hours. Used in research contexts for muscle growth studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

43/100

Useful IGF-1R probe with extended half-life but limited novelty and a thin clinical evidence base

Look, IGF-1 LR3 earns its place in a serious lab not because it’s exciting right now, but because it’s the cleanest available probe for IGF-1 receptor biology when extended bioavailability is the requirement. The core engineering is tidy: a 13-residue N-terminal extension combined with Glu-to-Arg substitution at position 3 substantially reduces binding to IGF binding proteins, pushing plasma half-life from roughly 12-15 hours for native IGF-1 to 20-30 hours for LR3. For cell culture work, that extended window matters practically. For in vivo rodent studies, you get more stable receptor occupancy without the dosing burden native IGF-1 imposes. GroPep originally developed it for mammalian cell growth media in the 1990s and that lineage is visible in how it behaves.

That said, the mechanism isnt novel by any stretch. IGF-1R signals through canonical PI3K/Akt/mTOR, and that territory is well-saturated in the literature. We’re not learning anything structurally new about IGF-1 biology by using LR3 that couldn’t be learned with native IGF-1 and careful protocol design. The value here is entirely pharmacokinetic convenience, not mechanistic novelty. The IGFBP-reduction strategy was a real innovation when it was first proposed; in 2026, it’s standard receptor pharmacology.

Where things get complicated is the translational picture. The IGF-1 axis is genuinely important in growth disorders, sarcopenia, and metabolic biology, and theres legitimate investigator interest in how IGF-1 modulation affects muscle protein synthesis and anabolic signaling in aging models. But the clinical base for LR3 specifically is thin. Mecasermin (native IGF-1) has formal regulatory data in severe primary IGF-1 deficiency; LR3 does not have a corresponding trial base. And the chronic-elevation safety concern is real, not precautionary boilerplate: sustained IGF-1 pathway activation is mechanistically connected to increased cancer risk and acromegalic features. That’s not a reason to avoid the compound as a research tool, but it firmly limits how aggressive a chronic-protocol investigator can be.

Differentiation within its niche is reasonable. Des(1-3)IGF-1 competes for some of the same in vitro applications, but LR3 is the dominant form in research catalogs and the more consistently cited analog across cell culture and rodent literature. For investigators specifically probing IGFBP-independent IGF-1R activation, it’s the practical default.

Honestly, we see this in the useful-but-not-urgent tier. Its bench value for IGF-1R biology, muscle research, and metabolic signaling programs is real and not overstated. But novelty is low, the evidence base for systemic investigational use is underdeveloped, and the safety constraints mean no major clinical program is going to be built on LR3 in its current form. Worth stocking for a serious GH-axis or muscle biology program. Dont expect it to anchor a novel research agenda on its own.

Novelty

35

Mechanism promise

40

In-category differentiation

55

Evidence quality

40

Translational signal

35

Research bench value

58

Rationale LR3’s IGFBP-reduction engineering is pharmacokinetically rational and it remains the dominant form for IGF-1R research requiring extended bioavailability, but the underlying mechanism is decades-old canonical PI3K/Akt/mTOR signaling with no novel target; formal human clinical data for the LR3 variant specifically is sparse, and chronic-elevation safety concerns actively constrain translational ambition.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Long Arg3 IGF-1 analog

A long-acting analog of IGF-1 with N-terminal extension and Arg3 substitution that reduces IGFBP binding and extends plasma half-life.

Abstract

IGF-1 LR3 (Long R3 IGF-1; CAS 946870-92-4; molecular weight 9111) is a recombinant analog of human IGF-1 with two structural modifications: a 13-residue N-terminal extension derived from the methionyl-N-terminal region of porcine GH, and substitution of arginine for glutamic acid at position 3. Both modifications reduce binding to IGF binding proteins (IGFBPs), which extends the plasma half-life and increases free bioavailable IGF-1 activity at IGF-1 receptors. The compound was originally developed for cell culture applications (mammalian cell growth media); research-grade availability supports investigational use. Pharmacokinetics: plasma half-life approximately 20 to 30 hours (versus 12 to 15 hours for native IGF-1). The compound is sold as a research chemical at concentrations typically 1 mg/mL. Investigational doses for performance applications range widely (20 to 100 micrograms per day) but the safety profile of long-term IGF-1 elevation is poorly characterized; chronic IGF-1 elevation is implicated in increased cancer risk and acromegalic features.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-087Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Methylene Blue

Plain-language summaryIntrigue 75 / 100

Methylene blue is a phenothiazine dye used historically for malaria, methemoglobinemia, and septic shock. At low doses it serves as an alternative electron donor in mitochondria, supporting energy production when normal pathways are impaired. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

53/100

Old phenothiazine with a genuine low-dose mitochondrial story; speculative cognitive signal but solid bench utility

Look, methylene blue is a weird one. It’s the oldest synthetic pharmaceutical compound still in active use, first synthesized in 1876, and its continued relevance is more interesting than its history suggests. The thing that matters for modern research isn’t the methemoglobinemia indication or the old antimalarial work. It’s the low-dose electron-cycling story, and thats worth taking seriously.

Here’s the mechanism as best we understand it: at low doses, methylene blue acts as an electron donor to Complex III of the mitochondrial electron transport chain, bypassing dysfunctional Complex I and Complex II. For conditions where mitochondrial dysfunction is upstream of neurodegeneration, that’s a genuinely useful probe mechanism, not a hand-wavy “supports mitochondria” claim. The Gonzalez-Lima group at UT Austin has published the most credible low-dose cognitive work, documenting improvements in rodent models of TBI, aging, fear extinction, and memory consolidation. The compound also appears to inhibit tau aggregation through a separate pathway, which is what pulled it into the Alzheimer’s space as a therapeutic candidate and gave it a second mechanistic identity worth tracking independently.

Dose-dependence here is important and a bit tricky to work around experimentally. High doses produce MAO inhibition and real serotonin syndrome risk, which complicates stack protocols and confounds signal if youre not careful about where you sit on the curve. Low-dose experiments need to be precisely calibrated. The blue staining effect on tissues and excreta is cosmetically obvious and can unmask participant blinding in clinical trials, a methodological headache that’s shown up more than once in the published discussion sections.

On the clinical side: the TauRx program used leucomethylthioninium, a reduced form, in phase 2 and phase 3 Alzheimer’s trials. Phase 2 signal was real and drew serious attention. Phase 3 confirmation was inconsistent. That outcome puts methylene blue in a familiar position: multi-lab preclinical is solid, small-N human cognitive signal exists but is modest, and replication is still genuinely in progress across several independent groups.

What we actually like here is the bench utility. Methylene blue is cheap, readily sourced at pharmaceutical grade, and provides a clean pharmacological tool for probing mitochondrial redox biology. If you’re building experiments around mitochondrial dysfunction in neurodegeneration, this belongs in the toolkit. We don’t think it’s a frontier compound, and we don’t think the cognitive signal is anywhere near settled. But it earns its place as a niche probe with a real mechanistic story and a well-characterized profile that makes it genuinely useful as a research instrument.

Novelty

40

Mechanism promise

65

In-category differentiation

55

Evidence quality

50

Translational signal

45

Research bench value

65

Rationale Ancient compound elevated by a mechanistically credible low-dose electron-donor story; preclinical is multi-lab and solid but the human cognitive signal remains modest and contested, placing it firmly in niche-probe territory rather than the novel-frontier tier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phenothiazine dye / electron donor

A phenothiazine dye used historically as an antimalarial and methemoglobinemia treatment, with mitochondrial electron-cycling activity at low doses for cognitive applications.

Abstract

Methylene blue (methylthioninium chloride; CAS 61-73-4; molecular formula C16H18ClN3S; molecular weight 319.85) is a phenothiazine dye with the longest pharmaceutical history of any synthetic compound (first synthesized 1876). The compound is FDA-approved for methemoglobinemia (high-dose, 1-2 mg/kg IV) and has historical use as an antimalarial. Low-dose methylene blue (0.5 to 4 mg/kg orally) has been studied for cognitive enhancement, traumatic brain injury, and Alzheimer disease, based on the compound’s mitochondrial electron-cycling activity (donates electrons to Complex III, bypassing dysfunctional Complex I/II). Pharmacology is complex and dose-dependent; high doses produce MAO inhibition and serotonin syndrome risk. Low-dose cognitive applications use 5 to 20 mg orally. The compound stains tissues and excreta blue, which is cosmetically obvious but harmless.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-122Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Kisspeptin

Plain-language summaryIntrigue 86 / 100

Kisspeptin is a hypothalamic neuropeptide that triggers GnRH release. It is the master regulator of puberty and reproductive hormones. Investigated for anovulatory infertility, hypogonadism, and reproductive disorders. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

58/100

Canonical KISS1R probe with strong human translation but limited novelty after two decades of characterization

Kisspeptin’s story starts in 2003, when loss-of-function KISS1 mutations were identified as the cause of idiopathic hypogonadotropic hypogonadism. That was genuinely exciting science. A single neuropeptide turned out to be the master switch for GnRH neuron firing, controlling puberty onset, menstrual cyclicity, the whole reproductive axis. The mechanism is clean and the biology is unambiguous: KISS1R agonism drives pulsatile GnRH release, which drives LH and FSH, which drives gonadal function. We like that story a lot.

What we dont like, from a research-merit standpoint, is that this story is now over 20 years old. The Cambridge group and others have done extensive characterization. Multiple groups have replicated the GnRH axis response across populations and experimental conditions. The mechanism is not in dispute. Thats actually the problem for novelty scoring. When the mechanism is settled and the primary application is the obvious one, you’re not on the frontier anymore.

Where kisspeptin remains genuinely useful is as a research tool for studying GnRH neuron dynamics. If your program involves hypothalamic neuroendocrinology, including puberty timing, functional hypothalamic amenorrhea, or energy-sensing crosstalk with the reproductive axis, kisspeptin is the canonical probe. There’s no replacement for it in that role. The kisspeptin-10 fragment is particularly useful for controlled, short-duration axis stimulation experiments where you want a tight pharmacokinetic window.

The fertility application is real and worth knowing. Several groups, including the London group with Lim et al. leading much of the clinical work, have explored kisspeptin-54 as an ovulation trigger in IVF. The OHSS-reduction angle has genuine rationale: because kisspeptin acts upstream through endogenous GnRH rather than exogenous LH, there’s a theoretical and some empirical advantage in high-responder populations. Effect size is real in the published trials. But we’re looking at phase 2 data, modest N, and a therapeutic problem that already has multiple established solutions. A phase 3 program is what’s needed to move this forward, and thats not there yet.

The emerging data on extrareproductive kisspeptin signaling, including metabolic effects, mood, and some interesting fMRI work on social bonding responses, adds a layer of interest. But these are exploratory signals, not yet a research program most labs would build around kisspeptin specifically. Honestly, this scores where it does because it’s a real neuropeptide with well-replicated human pharmacology and solid probe value in its domain, but the primary biology is settled and the clinical development path is narrow.

Novelty

45

Mechanism promise

55

In-category differentiation

65

Evidence quality

60

Translational signal

65

Research bench value

65

Rationale Kisspeptin is the master upstream regulator of the GnRH axis with well-replicated human pharmacology, scoring solidly on differentiation and translational signal as the canonical KISS1R probe; novelty is genuinely low after 20 years of active characterization, pulling the overall into the established-active tier rather than the frontier.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Hypothalamic neuropeptide / KISS1R agonist

An endogenous neuropeptide encoded by the KISS1 gene, master regulator of GnRH neuron firing and reproductive function.

Abstract

Kisspeptin (kisspeptin-54 and shorter active fragments including kisspeptin-10; encoded by the KISS1 gene) is an endogenous peptide identified in 2003 as the master regulator of GnRH neuron firing in the hypothalamus, controlling reproductive function and pubertal onset. Loss-of-function mutations in KISS1 or its receptor KISS1R produce hypogonadotropic hypogonadism. Exogenous kisspeptin administration stimulates LH and FSH release through GnRH neuron activation. The compound has been studied as a fertility therapeutic (induction of ovulation in functional hypothalamic amenorrhea) and as a research probe for reproductive neuroendocrine function. Pharmacokinetics: plasma half-life of kisspeptin-54 is ~30 minutes; kisspeptin-10 has shorter half-life. Research doses are highly variable; clinical trial doses range 0.01 to 6.4 nmol/kg IV.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-138Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Magnolia Bark (Honokiol/Magnolol)

Plain-language summaryIntrigue 50 / 100

Magnolia bark contains the biphenyl compounds honokiol and magnolol, which positively modulate GABA-A receptors and produce mild anxiolytic and sleep-promoting effects. Used in traditional Chinese medicine. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

33/100

Mature botanical anxiolytic with an interesting non-benzo GABAergic angle but thin human evidence and no clear edge over alternatives

Look, magnolia bark has been a fixture in traditional Chinese medicine for centuries, and the active constituents, honokiol and magnolol, have accumulated a solid if unspectacular literature over the past few decades. What we find genuinely interesting here is the mechanism: both biphenyls act as positive allosteric modulators at GABA-A receptors, but through a binding site distinct from the classical benzodiazepine site. Thats not nothing. The neurosteroid-adjacent binding pocket is an active area of inquiry, and compounds that engage it without benzo-site pharmacology are worth watching in anxiolytic research.

Here’s the thing though. This is a botanical extract, which means you’re working with a mixture of honokiol and magnolol in variable ratios depending on sourcing, extraction method, and batch. That matters enormously for any serious bench work. The preclinical literature largely uses isolated honokiol or isolated magnolol, not standardized bark extract, so translating rodent data to an extract formulation introduces real uncertainty about which constituent is driving which effect and at what concentration.

The evidence base is multi-lab at the preclinical level. Several groups have confirmed GABAergic activity for both compounds in rodent behavioral models, and honokiol’s NF-kB inhibitory activity shows up across independent labs as well. What’s missing is solid human clinical data. The few small human trials that exist report modest anxiolytic and sleep-promoting effects, but nothing that would move the needle for a serious investigator. Effect sizes are small, N is small, and replication is thin. Honestly, the human signal is closer to preliminary than compelling.

Differentiation is a real problem. In the botanical anxiolytic space, magnolia bark competes with kava (which has a cleaner human evidence base for anxiolysis), ashwagandha (which has multiple reasonably-designed trials behind it), and passionflower (which hits overlapping GABAergic targets). There’s no dimension where magnolia bark clearly outperforms the field. The non-benzo binding site is interesting in principle, but if you need a clean probe for that site, you’d reach for a neurosteroid analog or a well-characterized synthetic tool, not an herbal extract with batch-to-batch variability.

What we’d say to a bench investigator: isolated honokiol, not the bark extract, could have real probe value in the narrow context of GABA-A PAM research outside the benzo site. As a botanical formulation, its hard to use rigorously, the human evidence is underwhelming, and the anxiolytic space is crowded with better-characterized alternatives. Not the worst entry in the library. Not interesting enough to prioritize over the compounds where the evidence and novelty actually line up.

Novelty

28

Mechanism promise

42

In-category differentiation

32

Evidence quality

35

Translational signal

28

Research bench value

35

Rationale The non-benzodiazepine GABA-A PAM binding site earns mechanism credit, but extract-format variability, a crowded botanical anxiolytic field, and underwhelming human clinical data drag every other axis down; calculated overall of 33 sits below the OTC herb cap so no cap binds.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Botanical with biphenyl active constituents

Bark of Magnolia officinalis containing the biphenyl compounds honokiol and magnolol with anxiolytic and sleep-promoting activity through GABAergic mechanisms.

Abstract

Magnolia bark (Magnolia officinalis bark) contains the biphenyl compounds honokiol and magnolol as the principal active constituents. Both compounds show GABA-A receptor positive allosteric modulation through binding sites distinct from the benzodiazepine site. Honokiol additionally shows anti-inflammatory and antioxidant activity through NF-kB inhibition and direct radical scavenging. The compound has been studied for anxiety, sleep, and inflammatory conditions. Doses are typically 200 to 500 mg of standardized bark extract per day.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-154Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Esketamine

Plain-language summaryIntrigue 82 / 100

Esketamine, sold as Spravato, is the S-enantiomer of ketamine purified out as a single isomer. Approved in 2019 as an intranasal spray for treatment-resistant depression. About twice as potent as racemic ketamine at NMDA receptors. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

61/100

FDA-approved rapid antidepressant with live mechanistic debate around stereochemistry and HNK metabolite signal

Look, esketamine occupies a strange position in a research library. It’s an FDA-approved Schedule III drug with a real REMS program, multiple Phase 3 RCTs behind it, and the only formal regulatory endorsement in the rapid-acting antidepressant class. That’s legitimate standing. But the question for bench investigators is whether the compound is still generating new science, or whether the interesting questions have migrated somewhere downstream and esketamine is now mostly a clinical asset with a closed mechanistic story. The honest answer is: it’s somewhere in between.

The still-live science centers on mechanism. Whether the antidepressant effect comes from direct NMDA channel block, downstream AMPA potentiation, or the (2R,6R)-hydroxynorketamine metabolite that may bypass NMDA entirely is genuinely unresolved. The Zanos et al. 2016 Nature paper on HNK sparked a real fight that hasnt been settled, and esketamine is relevant to that fight precisely because its stereospecificity lets investigators parse contributions that racemic ketamine muddles. If you’re working on rapid-antidepressant mechanism, enantiomeric comparisons between S- and R-ketamine give you a probe you can’t replicate with the racemate.

The differentiation case is complicated. Esketamine has the FDA stamp and standardized intranasal delivery, but IV racemic ketamine is still widely used off-label, often preferred clinically because of cost and dosing flexibility. More pressingly, the emerging R-ketamine story from the Hashimoto lab argues that the R-enantiomer may produce antidepressant effects without dissociation, which if confirmed would directly challenge esketamine’s clinical position and make the stereochemistry question more urgent for research programs, not less.

Evidence quality is solid. The TRANSFORM and SUSTAIN trial programs gave esketamine multiple Phase 3 wins, and real-world post-approval data is accumulating. The methodological criticisms are legitimate, the open-label responder enrichment designs took pointed criticism at the FDA advisory committee level, but the compound cleared the bar and is being used on patients with treatment-resistant depression. That’s real translational signal, specifically in a population where alternatives are genuinely exhausted.

Where the score pulls back is novelty and conditional bench utility. Ketamine pharmacology has been in the literature since the 1960s. If your research question is not specifically about stereochemistry, enantiomeric dissociation, or NMDA-independent rapid antidepressant pathways, esketamine doesn’t open doors the racemate hasn’t already touched. What we like: unresolved mechanistic questions, enantiomeric probe specificity, FDA-validated clinical effect in a hard population. What we dont like: REMS overhead for research access, and the sense that the frontier has moved toward HNK and downstream plasticity targets rather than the parent compound itself.

Novelty

40

Mechanism promise

65

In-category differentiation

58

Evidence quality

70

Translational signal

75

Research bench value

65

Rationale Novelty is limited by decades of ketamine literature, but esketamine earns real points for FDA approval, well-documented Phase 3 evidence, and the genuinely unresolved mechanistic fight over whether the antidepressant signal traces to NMDA block, AMPA potentiation, or the (2R,6R)-HNK metabolite. Score reflects an established compound with meaningful bench utility for stereochemistry and rapid-antidepressant mechanism research, pulled back by REMS overhead, aging underlying pharmacology, and a research frontier that is visibly migrating toward metabolite biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

S-enantiomer NMDA antagonist

The (S)-enantiomer of ketamine, FDA-approved as Spravato (intranasal) for treatment-resistant depression.

Abstract

Esketamine (Spravato; CAS 33643-46-8) is the (S)-enantiomer of ketamine, FDA-approved in 2019 as an intranasal formulation for treatment-resistant depression and as adjunctive treatment for major depressive disorder with acute suicidal ideation (2020). The (S)-enantiomer carries higher NMDA receptor affinity than the (R)-enantiomer; the racemic ketamine is approximately 60 percent (S)-enantiomer activity. Pharmacokinetics: intranasal bioavailability ~48 percent; plasma half-life 7 to 12 hours. Approved doses are 56 to 84 mg intranasal twice weekly initially, tapering. Schedule III. REMS distribution program due to dissociation and abuse risk.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-171Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
L-Methylfolate (5-MTHF)

Plain-language summaryIntrigue 60 / 100

L-methylfolate (5-MTHF) is the active form of folate, bypassing the MTHFR enzyme that some patients have polymorphisms in. Used for depression augmentation (especially in MTHFR variants) and for pregnancy. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Active folate / 5-methyltetrahydrofolate

The active form of folate (5-methyltetrahydrofolate) used clinically for major depression adjunct and for individuals with MTHFR polymorphisms.

Abstract

L-Methylfolate (5-methyltetrahydrofolate, 5-MTHF; CAS 31690-09-2) is the active form of folate (vitamin B9), bypassing the methylenetetrahydrofolate reductase (MTHFR) step that is impaired in individuals with C677T or A1298C MTHFR polymorphisms. The compound is FDA-approved as Deplin (medical food) for major depressive disorder, particularly in patients with low folate status or MTHFR polymorphisms. Mechanism is provision of methyl groups for SAM-e synthesis and downstream methylation, including monoamine neurotransmitter synthesis. Doses are typically 1 to 15 mg per day; clinical use for depression is at the high end (7.5 to 15 mg).

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-186Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Sertraline

Plain-language summaryIntrigue 67 / 100

Sertraline (Zoloft) is one of the most widely prescribed psychiatric medications on the planet. Pfizer brought it to market in 1991 as a follow-on to Prozac with a slightly different shape and a slightly different side-effect profile. The main action is the standard SSRI move: block serotonin from being recycled back into the cell that fired it. A small bonus is mild blockade of the dopamine pump, which a few researchers credit with the somewhat brighter subjective profile some patients report compared to other SSRIs. Approved for depression, OCD, panic, PTSD, social anxiety, and premenstrual mood disorder. Generally considered first-line and reasonably well tolerated. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

45/100

Clinically dominant reference SSRI with exhausted novelty and modest bench utility as a comparator compound

Look, sertraline is probably the most clinically well-validated compound in our library, and thats exactly the problem. When a molecule has been prescribed to tens of millions of people across six approved indications since 1991, the bench science has long since moved on. We’re not here to revisit what we already know about SERT inhibition. Pfizer’s chemists synthesized this in 1977; the basic pharmacology was settled before most active investigators were in graduate school.

The mechanism is nanomolar SERT inhibition (Ki approximately 0.3 nM) with a minor DAT component (Ki approximately 25 nM) that distinguishes it somewhat from the rest of the SSRI class. We think the DAT angle is genuinely the most scientifically interesting thing about sertraline, and it’s mostly a footnote. The 5-HTTLPR literature tried to personalize SSRI prescribing for decades and largely failed; the monoamine hypothesis has taken its share of hits; and anything new you want to ask about SERT biology has better, more selective probes available today. The research conversation has moved toward network-level antidepressant mechanisms, rapid-acting approaches, and psychoplastogens that make single-target reuptake inhibition look like a solved problem.

Where sertraline does hold genuine bench value is as a reference standard. The dichlorophenyl moiety is a frequently-appearing structural feature in SSRI SAR programs, and if you’re running SERT binding assays sertraline is a logical comparator. It’s also a well-characterized positive control in rodent FST and TST models of depression and anxiety, which matters when you want a known-good anchor alongside whatever experimental compound you’re actually studying. That’s real utility, but it’s the utility of a ruler, not the utility of what you’re measuring.

The evidence and translational scores are, honestly, among the highest in the library. Multiple phase 3 RCTs, regulatory approvals across major jurisdictions, replicated over three decades. The irony is that this is precisely why sertraline scores poorly on novelty and mechanism: the literature is exhausted, not exciting. A serious investigator doesn’t wake up thinking they should study sertraline. They wake up thinking they need sertraline as a control condition.

Sourcing is trivial, stability is excellent, the CYP interaction profile is thoroughly mapped (2D6 inhibition present but weaker than fluoxetine or paroxetine), and there are no surprises in handling. None of that makes it a compelling primary research target; it makes it convenient. We score it at 45 because the bench reference value and the sterling clinical record pull it above the floor, but this is not where a serious research program directs its primary attention. Use it as the comparator, not the subject.

Novelty

18

Mechanism promise

22

In-category differentiation

28

Evidence quality

88

Translational signal

82

Research bench value

55

Rationale Stellar evidence and translational scores reflect decades of replicated phase 3 data across six indications, but these are entirely offset by near-zero novelty and mechanism interest; sertraline’s bench value is real but confined to reference-standard roles in SERT binding studies and animal model controls. No structural cap applies.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective serotonin reuptake inhibitor

A naphthylamine SSRI with mild dopamine reuptake inhibition; one of the most prescribed psychiatric medications worldwide.

Abstract

Sertraline ((1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine; CAS 79617-96-2; molecular formula C17H17Cl2N; molecular weight 306.23) is a tetrahydronaphthalene SSRI synthesized at Pfizer in 1977 and approved by the FDA in 1991 under the trade name Zoloft. SERT affinity is nanomolar (Ki approximately 0.3 nM); the compound exhibits weak dopamine transporter inhibition (Ki approximately 25 nM) that is unusual within the SSRI class and may contribute to a subtly different subjective profile. Plasma half-life is 22 to 36 hours; the principal metabolite N-desmethylsertraline is pharmacologically active but with reduced SERT affinity. Hepatic metabolism is via CYP2B6, CYP2C19, CYP2D6, and CYP3A4; clinically relevant CYP2D6 inhibition exists but is weaker than fluoxetine or paroxetine. Approved indications include major depressive disorder, OCD, panic disorder, PTSD, social anxiety disorder, and premenstrual dysphoric disorder. Used as a reference compound in SERT binding studies and animal models of depression and anxiety; the dichlorophenyl moiety is a target structural feature in numerous SSRI structure-activity relationship studies.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-202Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Desipramine

Plain-language summaryIntrigue 53 / 100

Desipramine (Norpramin) is the active leftover of imipramine, FDA-approved in 1964, and the most norepinephrine-selective tricyclic antidepressant ever brought to market. The shift in selectivity comes from removing one methyl group from imipramine. The strongly noradrenergic profile makes it one of the more activating tricyclics and useful in attention deficit research, although it never gained an ADHD label. Compared to its parent it has lower anticholinergic and antihistamine burden, so it is somewhat better tolerated, but it shares the cardiac conduction problems of the whole tricyclic class and overdose is dangerous. Used in treatment-resistant depression and some neuropathic pain protocols. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

44/100

The canonical NET-selective TCA; useful as a noradrenergic reference probe but essentially exhausted as a research frontier

Look, desipramine is about as established as it gets in the TCA class. FDA-approved in 1964, it’s been the reference standard for NET-selective tricyclic pharmacology for sixty years. That dual status, canonical probe on one hand and dated workhorse on the other, is exactly what drives the score here.

The NET selectivity is real and it matters. A Ki of roughly 0.83 nM at NET versus 17 nM at SERT gives you a selectivity ratio around 20-fold, which is genuinely useful if you’re trying to dissect noradrenergic from serotonergic contributions in a mixed-reuptake experiment. Compared to imipramine, the parent compound, desipramine sheds meaningful muscarinic (M1 Ki around 200 nM) and H1 load while keeping the NET hit clean. For any investigator running catecholamine reuptake assays, building pharmacological controls, or studying NE dynamics in pain or ADHD-relevant circuits, its position as the canonical NET-selective TCA is hard to displace within that specific context. Thats the bench case for having it in the library.

But thats also where the excitement ends. The mechanism, NET reuptake inhibition, has been understood for sixty years. The binding kinetics are fully characterized, the downstream noradrenergic effects are mapped, and the CYP2D6/CYP2E1 metabolism profile is textbook. What we dont like is that atomoxetine and reboxetine both exist now, offering higher NET selectivity without the TCA off-target load. For pure noradrenergic questions, those compounds have largely superseded desipramine except in historical comparisons or when the TCA scaffold itself is under study.

The evidence base is enormous. Multiple phase 3 trials, decades of replicated clinical data, strong meta-analytic signal for MDD. Translational signal is unambiguous in the sense that it works in people and that fact is exhaustively documented. But from a research novelty standpoint, a large evidence base on a 60-year-old compound means less remaining question to answer. There’s no frontier in the depression indication, the neuropathic pain angle is mature, and the ADHD off-label use lives in the shadow of better-characterized and more selective tools.

We think desipramine earns its place in the library as a reference compound and nothing more. Investigators comparing noradrenergic agents, running assay controls, or building pharmacological models of NE reuptake will want it on the shelf. For anything asking a genuinely new question about human biology, the novelty and mechanism scores drag the overall to where it belongs: a well-characterized, historically important, presently limited research tool.

Novelty

18

Mechanism promise

28

In-category differentiation

40

Evidence quality

72

Translational signal

68

Research bench value

60

Rationale Desipramine scores well on evidence and translational signal because its pharmacology is thoroughly characterized over six decades, but those same qualities crush its novelty and mechanism scores. Its bench value is real but narrow: it functions as a reference standard for NET-selective TCA comparisons, not as a frontier compound worth pursuing for new biology.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Tricyclic antidepressant (secondary amine)

The N-desmethyl active metabolite of imipramine; the most NET-selective TCA in clinical use.

Abstract

Desipramine (3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine; CAS 50-47-5; molecular formula C18H22N2; molecular weight 266.38) is the N-desmethyl active metabolite of imipramine, approved by the FDA in 1964 under the trade name Norpramin. The compound is the most NET-selective TCA in clinical use (NET Ki approximately 0.83 nM, SERT Ki approximately 17 nM, ratio approximately 20). Off-target activity is reduced compared to imipramine: muscarinic (M1 Ki approximately 200 nM), H1 (Ki approximately 60 nM), and alpha-1 (Ki approximately 100 nM) antagonism are all weaker than the parent compound, producing a cleaner profile though still TCA-like. Plasma half-life is 15 to 24 hours; metabolism is via CYP2D6 and CYP2E1. Approved for major depressive disorder; used at higher doses (150 to 300 mg) for moderate-severe depression, at lower doses for ADHD (off-label) and neuropathic pain. Sodium channel block and consequent cardiotoxicity in overdose remain limitations. Used as the canonical NET-selective TCA in mechanism studies and as a reference compound for noradrenergic pharmacology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-219Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Olanzapine

Plain-language summaryIntrigue 64 / 100

Olanzapine (Zyprexa) is the closest pharmacological cousin of clozapine, brought to market by Eli Lilly in 1996 specifically to capture clozapine’s effectiveness without its agranulocytosis risk. That worked: olanzapine is reliably one of the more effective antipsychotics for schizophrenia and acute mania, and patients do not need weekly blood draws. The trade-off is the worst metabolic profile of any drug in its class. Patients on olanzapine routinely gain 10 to 30 pounds, develop dyslipidemia, and progress to type 2 diabetes at high rates. Used for schizophrenia, acute mania, and treatment-resistant depression in combination with fluoxetine (the Symbyax product). The recent intramuscular long-acting injection (Zyprexa Relprevv) carries an unusual risk of post-injection delirium and sedation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

Mature reference atypical antipsychotic with settled science and minimal frontier research value

Look, the compound’s story begins and essentially ends in 1996, when Eli Lilly got FDA approval for Zyprexa. Thats almost thirty years of data, which is simultaneously olanzapine’s greatest asset and its most damning liability as a research target. The evidence base is unimpeachable. CATIE, multiple phase 3 head-to-heads, decades of real-world pharmacovigilance across millions of patients: if you want to know what olanzapine does, the literature tells you with unusual clarity. This is not a compound with ambiguous effects or contested mechanisms.

The receptor profile is genuinely broad and worth understanding in structural terms. D2 (Ki approximately 11 nM), 5-HT2A (Ki approximately 4 nM), H1 (Ki approximately 0.087 nM, among the tightest H1 affinities in clinical antipsychotic use), plus alpha-1, muscarinic, and multiple serotonin subtypes. That H1 affinity is the most pharmacologically interesting feature: combined H1 and 5-HT2C antagonism produces a metabolic syndrome signature that is the worst of any commonly used antipsychotic, with mean weight gain of 4 to 12 kg over 12 weeks and incident type 2 diabetes well-documented. If your research program is specifically interrogating hypothalamic H1/5-HT2C co-blockade as a driver of metabolic dysregulation, olanzapine is a legitimate and well-characterized probe for that question.

The structural comparison with clozapine also has real value for SAR work. Olanzapine is essentially clozapine with a thieno ring substitution that eliminates the agranulocytosis liability while preserving the broad-spectrum atypical pharmacology. For investigators studying what the clozapine scaffold actually buys you mechanistically, comparing these two compounds is worth pulling apart carefully. Clozapine remains the efficacy gold standard in treatment-resistant schizophrenia; olanzapine is the closest approximation you can study without REMS infrastructure.

What we don’t like: the novelty is gone. The mechanism of atypical antipsychotic action via D2/5-HT2A ratio modulation is settled territory, worked out through the 1990s and confirmed repeatedly since. Theres no fresh frontier here, no emerging indication driving genuine bench excitement, no mechanistic surprise hiding in the data. The compound functions as a reference comparator in clinical trials precisely because it is established science, and that same quality makes it a low-priority target for investigators trying to do something new.

The most active current research angle is low-dose antiemetic use, particularly as a triplet-regimen adjunct for chemotherapy-induced nausea and vomiting. That’s real, has plausible mechanistic support via 5-HT3 and 5-HT2 blockade, and ASCO guidelines now reflect it. But it’s an adjacent application of settled pharmacology, not a discovery. We stock olanzapine as a reference compound. For a CNS pharmacology program that needs a canonical broad-spectrum atypical for mechanistic comparison or metabolic interrogation, it earns its place on the shelf. For investigators hunting genuinely fresh targets, the literature here is already written.

Novelty

18

Mechanism promise

32

In-category differentiation

48

Evidence quality

85

Translational signal

80

Research bench value

55

Rationale Olanzapine scores high on evidence and translational signal because it is an FDA-approved drug with three decades of replicated clinical data, but both novelty and mechanism promise are low: the D2/5-HT2A atypical pharmacology story has been understood since the clozapine era, and there is no emerging indication or mechanistic surprise driving serious bench interest. Bench value is moderate because it functions as a canonical reference compound and a legitimate probe for H1/5-HT2C-driven metabolic effects.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Atypical antipsychotic

A thienobenzodiazepine atypical antipsychotic structurally and mechanistically related to clozapine, without the agranulocytosis risk.

Abstract

Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; CAS 132539-06-1; molecular formula C17H20N4S; molecular weight 312.43) is a thienobenzodiazepine atypical antipsychotic developed at Eli Lilly and approved by the FDA in 1996 under the trade name Zyprexa. The receptor profile is closely related to clozapine: D2 (Ki approximately 11 nM, higher affinity than clozapine), 5-HT2A (Ki approximately 4 nM), H1 (Ki approximately 0.087 nM, among the most potent in clinical use), alpha-1, muscarinic, 5-HT2C, 5-HT3, 5-HT6, 5-HT7. The structural difference from clozapine eliminates the agranulocytosis liability while preserving the broad-spectrum atypical pharmacology. Plasma half-life is 21 to 54 hours; metabolism is via CYP1A2 and direct glucuronidation. The compound carries the highest metabolic risk profile of any commonly used antipsychotic: dyslipidemia, weight gain (mean 4 to 12 kg over 12 weeks), and incident type 2 diabetes are well-documented, attributed to combined H1 and 5-HT2C antagonism. Approved for schizophrenia, bipolar I disorder, and treatment-resistant depression in combination with fluoxetine (Symbyax). Used as a reference broad-spectrum atypical antipsychotic.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-234Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 38 39 40 41 42 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.